Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer

BACKGROUND: The trastuzumab biosimilar CT-P6 has demonstrated equivalent efficacy and comparable safety to reference trastuzumab (RTZ) in clinical trials of human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC). Here, we present the first real-world comparison of CT-P6 v...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Soong June, Kim, Jee Hung, Ahn, Sung Gwe, Jeung, Hei-Cheul, Sohn, Joohyuk, Kim, Gun Min, Kim, Min Hwan, Kim, Seung Il, Park, Seho, Park, Hyung Seok, Kim, Ji Ye, Jeong, Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213064/
https://www.ncbi.nlm.nih.gov/pubmed/34150658
http://dx.doi.org/10.3389/fonc.2021.689587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213064/
https://www.ncbi.nlm.nih.gov/pubmed/34150658
http://dx.doi.org/10.3389/fonc.2021.689587

Ejemplares similares